NCT06533748 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06533748
Title	Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	St. Jude Children's Research Hospital
Indications	B-cell acute lymphoblastic leukemia lymphoblastic lymphoma
Therapies	Blinatumomab + Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Inotuzumab ozogamicin + Methotrexate + Vincristine Sulfate Blinatumomab + Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Hydrocortisone + Inotuzumab ozogamicin + Mercaptopurine + Methotrexate + Vincristine Sulfate Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Thioguanine + Vincristine Sulfate
Age Groups:	child \| adult
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Saint Francis Children's Hospital	RECRUITING	Tulsa	Oklahoma	74136	United States	Details
St. Jude Children's Research Hospital	RECRUITING	Memphis	Tennessee	38105	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT06533748Clinical Trial Detail